A
JANX icon

AlphaQuest’s Janux Therapeutics JANX Stock Holding History

AlphaQuest’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,855
Closed -$177K – 1020
2025
Q4 		$177K Buy
12,855
+5,535
+76% +$130K 0.01% 1511
2025
Q3 		$179K Sell
7,320
-2,378
-25% -$57.9K 0.01% 1465
2025
Q2 		$224K Buy
9,698
+9,440
+3,659% +$249K 0.02% 1055
2025
Q1 		$6.97K Buy
258
+140
+119% +$5.28K ﹤0.01% 1831
2024
Q4 		$6.32K Sell
118
-3,420
-97% -$181K ﹤0.01% 1553
2024
Q3 		$161K Sell
3,538
-2,257
-39% -$98.2K 0.01% 1153
2024
Q2 		$243K Buy
5,795
+4,372
+307% +$205K 0.03% 689
2024
Q1 		$53.6K Buy
+1,423
New +$31K 0.01% 924

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AlphaQuest's JANX Position: Q1 2026 in Review

AlphaQuest sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 12,855 shares — an estimated $177K sold.

AlphaQuest first reported a position in JANX in Q1 2024 and held it in 8 quarters. The position peaked at $243K in Q2 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • AlphaQuest reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 12,855 Janux Therapeutics shares in Q1 2026, an estimated $177K.
  • AlphaQuest first reported a position in Janux Therapeutics in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Janux Therapeutics position peaked at $243K in Q2 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.